Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes

• Published in: The New England journal of medicine Vol. 387; no. 16; pp. 1529 - 1531
• Main Authors: Senoo, Yuki, Kami, Masahiro, Arslanian, Silva A., Cox, David
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 20-10-2022
• Subjects: Age; Agonists; Body height; Body weight; Conflicts of interest; Diabetes; Diabetes mellitus (non-insulin dependent); Glucagon; Glucagon-like peptide 1; Growth hormones; Overweight; Pediatrics; United States > US; Pittsburgh Pennsylvania
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMc2211623

To the Editor:
Arslanian et al. (Aug. 4 issue)
1
report that a once-weekly subcutaneous injection of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, at a dose of 0.75 mg or 1.5 mg was superior to placebo in improving blood glucose control in overweight pediatric patients (10 to <18 years of age) with type 2 diabetes. Notably, 40% of the children were under 14 years of age. The average height of the children was 162.4±9.2 cm, which suggests that they had not yet reached their adult height. A previous study
2
of GLP-1 receptor agonists showed their potential role in an increase . . .